Viruses do not respect border

Outbreaks of viruses like ebola, hantavirus, and nipah are becoming part of a recurring pattern. A disease that begins in a forest village or ship can create cross-border concern.

Major Zoonotic Viruses 

Virus	Reservoir/Origin	Disease and Severity	Mode of Transmission	Current Significance
Ebola Virus	Believed to be maintained in wild animal reservoirs, with outbreaks occurring mainly in Central and West Africa.	Causes Ebola Virus Disease, characterised by severe systemic illness and an average case-fatality rate of nearly 50%.	Spreads between humans through direct contact with the blood, secretions, organs or other body fluids of infected persons.	Recent outbreaks in Central Africa show how conflict, displacement, unsafe burial practices, distrust of health workers and weak surveillance complicate containment efforts.
Hantavirus	A rodent-borne virus named after the Hantaan River region in South Korea.	Can cause Haemorrhagic Fever with Renal Syndrome or Hantavirus Pulmonary Syndrome, which may rapidly progress to respiratory failure and shock.	Humans are generally infected through exposure to aerosolised particles from rodent urine, droppings or saliva.	A reported cluster linked to the MV Hondius cruise ship highlighted how travel, enclosed environments and international contact tracing can turn a local outbreak into a global health concern.
Andes Hantavirus Strain	Primarily associated with rodents in South America.	Causes severe hantavirus pulmonary disease.	Unlike most hantaviruses, the Andes strain can spread to a limited extent through close person-to-person contact.	Its potential for human transmission makes outbreak monitoring and contact tracing especially important.
Nipah Virus	Mainly carried by fruit bats of the Pteropus genus.	Causes severe respiratory illness and encephalitis, with an estimated case-fatality rate of 40–75%.	Spreads through contact with infected animals or contaminated material and through close household or healthcare contact with infected persons.	Recurrent outbreaks in India and Bangladesh demonstrate that Nipah remains a persistent regional public-health threat.

The Vaccine Gap

• Limited Vaccine Availability: A licensed vaccine is available for only one major Ebola virus species.
• Major Unprotected Diseases: No licensed human vaccines currently exist for Bundibugyo Ebola, Nipah virus or hantavirus infections.
• Absence of Curative Treatment: Reliable curative treatment is generally unavailable once outbreaks begin.
• Public-Health Priority: Early detection, rapid isolation, contact tracing and strict infection-control measures remain crucial.

Building Preparedness: From Research to Vaccine
1. Basic Research

• Understanding the Pathogen: Researchers study how the virus enters human cells, causes disease and evades immune responses.
• Identifying Vaccine Targets: Scientific research identifies viral proteins capable of producing a protective immune response.
• Public-Sector Role: Much of this foundational research is conducted in publicly funded universities and national laboratories.

2. Industrial Translation

• Converting Research into Vaccines: Scientific discoveries must be transformed into safe, stable and usable vaccine products.
• Process Development: Manufacturers develop production methods that can consistently produce vaccines at a large scale.
• Quality and Regulation: Vaccine development requires quality control, regulatory documentation, safety assessment and approval.
• Clinical Testing: Candidate vaccines must undergo clinical trials to establish their safety, dosage and effectiveness.
• Distribution Planning: Manufacturing capacity, storage facilities and cold-chain systems must be developed before mass deployment.

Why Vaccine Development Lags
1. Restricted Technology Access

• Patents, proprietary know-how and specialised manufacturing systems limit access to advanced vaccine platforms.
• Production and regulatory capacity remain concentrated in a few countries and companies.

2. Clinical-Trial Difficulties

• Sporadic, short-lived and geographically limited outbreaks provide too few participants for conventional trials.
• Flexible methods such as ring-vaccination, adaptive trials and regional trial networks are therefore required.

3. Weak Commercial Incentives

• Small and uncertain markets, mainly in low-income regions, offer limited returns.
• High research, testing and manufacturing costs discourage private investment despite significant public-health benefits.

Closing the vaccine gap requires sustained public investment, open technology platforms, flexible clinical trials and stronger global cooperation—not merely emergency action after an outbreak begins.